PlasmaTech Biopharmaceuticals' Announces $10 Million

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PlasmaTech Biopharmaceuticals' Announces $10 Million Private Placement

DALLAS, TX and NEW YORK, NY --(Marketwired - May 06, 2015) -  PlasmaTech Biopharmaceuticals, Inc. ("PlasmaTech" or the "Company"), ( NASDAQ : PTBI ), announced today that it has entered into a definitive agreement with one institutional investor in a private placement of approximately $10 million of common stock at a price of $8.00 per share, or 1,250,000 shares.

In addition, the Company will issue to the investors warrants to purchase 625,000 shares of common stock. The warrants have an exercise price of $10.00 per share and are exercisable for 30 months from the closing date.

The offering is expected to close on or about May 11, 2015, subject to satisfaction of customary closing conditions.

H.C. Wainwright & Co. acted as the exclusive placement agent for the transaction.

The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock and shares issuable upon exercise of the warrants within 30 days of the closing date.

This release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

Further details of the placement will be described in a Current Report on Form 8-K to be filed with the SEC by the Company and all of the transaction documents will be attached to the Form 8-K.

About PlasmaTech: PlasmaTech is a biopharmaceutical company focused on advancing cell therapy and gene therapy for rare diseases. With its recently announced acquisition, PlasmaTech is pursuing a gene therapy for Sanfilippo Syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in mid-2015. In addition, the company is pursuing two additional proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of human plasma-derived therapeutics, including its proprietary alpha-1 protease inhibitor, SDF Alpha™. The company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™, with additional follow-on products in development. For more information, visit www.plasmatechbio.com .

Safe Harbor Statement This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 261

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 305

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 210

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 156

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 460

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 278

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 256

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading

Top 5 Most Recently Viewed Articles

Clene Inc. Set to Showcase Innovations at Key Conference

Updated Category News Views 149

Clene Inc. Ready for Emerging Growth Conference Presentation Clene Inc. (NASDAQ: CLNN), a pioneering clinical-stage biopharmaceutical company, is set to present at the Emerging Growth Conference. This upcoming event marks a significant opportunity for Clene to showcase its groundbreaking approach in the realm of mitochondrial health and neuroprotection, particularly with...

Continue Reading
Corbion Launches €10 Million Share Buyback Initiative for Employees

Updated Category News Views 223

Corbion Introduces a New Share Buyback Program Corbion N.V. is thrilled to announce its latest initiative, a share buyback program, set to repurchase ordinary shares for a total maximum value of €10 million and up to 580,383 shares. This strategic move underscores the company's commitment to supporting its employees while reinforcing its economic stability. Program...

Continue Reading
SPRY Therapeutics Celebrates Recognition with G2 Fall 2024 Badges

Updated Category News Views 251

SPRY Therapeutics achieved a significant milestone back in Fall 2024, snagging 12 badges from the G2 Reports for its groundbreaking AI-powered electronic medical record (EMR) system. This isn't just another award; it speaks volumes about their positioning across crucial areas like Physical Therapy, Medical Billing, Electronic Health Records (EHR), Patient Scheduling, and...

Continue Reading
Flanigan's Enterprises Showcases Impressive Earnings Growth

Updated Category News Views 137

Flanigan's Enterprises Reports Earnings Growth Flanigan's Enterprises, Inc., (NYSE AMERICAN: BDL) is recognized for its distinguished restaurants and retail liquor stores. The company recently showcased its financial performance for the latest 13-week and 39-week periods, and the results demonstrate substantial growth. Overview of Financial Performance For the 13 weeks...

Continue Reading
Continued Investigation into iRhythm Technologies' Management by KSF

Updated Category News Views 174

Ongoing Investigation of iRhythm Technologies New York based Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is actively investigating iRhythm Technologies, Inc. (NASDAQ: IRTC). The firm is probing potential breaches of fiduciary duty by the company’s directors and officers. The focus is on their responsibilities to shareholders in...

Continue Reading